CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2021-01-01
|
Series: | Opuholi Ženskoj Reproduktivnoj Sistemy |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/765 |